Skip to content

Study · Animal study (in vivo) · rat · 2007

4 results

[Preparation and properties of Talpha1 loaded injectable sustained release microspheres].

Zhu Y, Lu Y, Zhong YQ

Yao xue xue bao = Acta pharmaceutica Sinica1 Feb 2007

PMID17518054 (opens in a new tab)PepBankPUB-17518054
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In immunosuppressed rats, thymosin alpha‑1 microspheres significantly increased immunity, measured by the change of CD4+/CD8+.

    In plain wordsIn rats with a weakened immune system, thymosin alpha‑1 microspheres raised immune function.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseImmunity (CD4+/CD8+ ratio) in immunosuppressed rats
    Study

    ratn: not reported in source

    Immunosuppressed rats
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Talpha microspheres can increase significantly the immunity of immuno-suppressed rats.
    1 context sentence
    Summary · context
    The ratio of CD4+/CD8+ in blood was determined with flow cytometry and the pharmacodynamics of Ta, loaded microspheres was evaluated by the change of CD4+/ CD8+.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    Thymosin alpha‑1 bioactivity was conserved during encapsulation with glucose as outer water phase, but specific activity decreased slightly during in vitro release.

    In plain wordsIn lab tests, thymosin alpha‑1 kept its activity after encapsulation, but its activity fell a little during release.

    Peptide
    Thymosin alpha-1
    Outcome
    MixedBioactivity of thymosin alpha-1 after encapsulation and release
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The bioactivity of Talpha was conserved with glucose as outer water phase, but in the course of in vitro release, the specific activity of Talpha in the microspheres decreased a little.
    1 context sentence
    Summary · context
    The bioactivity of Talpha1 in the course of encapsulation process and in vitro release ware evaluated by CCK-8 method.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Other

    Two optimized PLGA microsphere formulations of thymosin alpha‑1 reached high drug entrapment efficiency.

    In plain wordsIn lab tests, two microsphere formulations held a high share of the thymosin alpha‑1 drug.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableDrug entrapment efficiency of microspheres
    Study

    n: not reported in source

    Outcome group
    Formulation, delivery and stability · Pharmacology

    Source sentences

    Summary
    The drug entrapment efficiency of two optimizing prescriptions containing 5% NaCl and 10% glucose as outer water phase were 87. 8% and 90. 2% , respectively.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cell-free)Pharmacokinetics

    Thymosin alpha‑1 PLGA microspheres released up to 90% of the drug cumulatively in one month in vitro.

    In plain wordsIn lab tests, the microspheres released up to 90% of thymosin alpha‑1 over one month.

    Peptide
    Thymosin alpha-1
    Outcome
    Not applicableCumulative release in one month
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Cumulative release in one month
    ≤ 90%
    microspheres

    Source sentences

    Summary
    The cumulated release in one month is up to 90%.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.